Sodium zirconium cyclosilicate increases serum bicarbonate concentrations among patients with hyperkalaemia: exploratory analyses from three randomized, multi-dose, placebo-controlled trials, Nephrol Dial Transplant (2021) 36: 871–883; doi.org/10.1093/ndt/gfaa158
In the originally published version of this manuscript, although all tables and figures were correct, several corresponding maintenance phase results were inaccurately recorded in the text using completers rather than ITT data. These errors are noted and listed in this corrigendum as follows:
The following paragraph under the “Maintenance of effects” heading, in the “Effects of SZC on serum bicarbonate” section should read: “Reductions in proportions of patients with serum bicarbonate <22 mmol/L during the CP continued to fall during the MP with an SZC dose of 15 g in HARMONIZE (Table 2; odds ratio, 0.30 [95% CI: 0.12, 0.75], P = 0.009 at 15 days, and 0.14 [95% CI: 0.03, 0.63], P = 0.005 at 29 days) and were preserved during the MP with an SZC dose of 10 g in HARMONIZE-Global (Table 2; odds ratio, 0.27 [95% CI: 0.10, 0.74], P = 0.011 at 15 days, and 0.19 [95% CI: 0.05, 0.67], P = 0.006 at 29 days).”.
The following text under the “Maintenance of effects” heading, in the “Effects of SZC on serum urea” heading should read: “the mixed-model derived 15- to 29-day LS mean changes from baseline were significantly decreased versus placebo for the SZC 10 g QD dose in HARMONIZE (Table 3)”.
The following text under the “Maintenance of effects” heading, in the “Effects of SZC on urine pH” heading should read: “the mixed-model derived 15 to 29-day LS mean changes from baseline were significantly increased versus placebo for the SZC 10 g and 15 g QD doses in HARMONIZE (Table 3)”.
These have now been corrected online.
doi: 10.1093/ndt/gfaa305